(Q36897036)

16 August 2017

1 reference

title

Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs (English)

1 reference

16 August 2017

0 references

1 reference

1 reference

James Dale

1

1 reference

16 August 2017

Nicola Alcorn

series ordinal

2

1 reference

16 August 2017

Hilary Capell

series ordinal

3

1 reference

16 August 2017

Rajan Madhok

series ordinal

4

1 reference

16 August 2017

publication date

1 August 2007

1 reference

Nature Clinical Practice Rheumatology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

450-8; quiz, following 478

1 reference

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

The efficacy and toxicity of combination therapy in rheumatoid arthritis. a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination therapy in rheumatoid arthritis: updated systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Can clinical trials in rheumatology be improved?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0562

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0562

1 reference

16 August 2017

1 reference